Drug Pricing Lab Drug Pricing Lab
  • Our Work
  • Learn
  • Tools
  • News
  • About
  • search
search
Sign up for updates
Join our mailing list to receive updates from the Drug Pricing Lab.
Thank you!
Thank you for signing up to receive news and information from the Drug Pricing Lab.
Return to Previous Page

Results for: Chemotherapies


News

Eli Lilly announces additional vial size to minimize waste

Chemotherapies
Manufacturers
Oncology
Eli Lilly analysis leads to introduction of new vial size.
American Journal of Health-System Pharmacy
May 11, 2017

Research

Hospital outpatient versus doctor office cost for physician administered cancer drugs

Chemotherapies
Costs of Care
Policy
A new analysis reviews several analyses of differential costs of care provided in the doctors’ offices and hospital outpatient settings.
Evidence Driven Drug Pricing Project
January 4, 2017

Research

Overspending driven by oversized single dose vials of cancer drugs

Chemotherapies
Drug Prices
Manufacturers
New analysis in BMJ looks at avoidable excess medicine and waste in top 20 U.S. cancer drugs and how to prevent it
Drug Pricing Lab
May 1, 2016

News

Expensive Oral Agents Responsible for Cost Shifting in Cancer

Chemotherapies
Drug Prices
Oral anticancer agents are being launched at significantly higher prices compared with a decade ago and has become a barrier for some patients.
The American Journal of Managed Care
April 29, 2016

News

What Is Coming in Specialty Pharmacy? A Look at the Near-Term Drug Pipeline

Chemotherapies
Drug Prices
Specialty Drugs
AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016 kicked off by delving into the near-term specialty pharmaceutical pipeline
The American Journal of Managed Care
April 20, 2016

Research

Part B Payment for Medicare Drugs

Chemotherapies
Drug Prices
Medicare
An analysis on why proposed changes to the system are being met with opposition and the impact for providers and patients.
Evidence Driven Drug Pricing Project
April 11, 2016

News

Report Finds Billions Wasted as Lifesaving Drugs are Thrown Away

Chemotherapies
Financials/ Profitabililty
Manufacturers
There is growing outrage over the billions of expensive drugs being thrown away simply due to one-size-fits-all packaging.
NBC News
March 16, 2016

Research

Pricing in the Market for Anticancer Drugs

Chemotherapies
Drug Prices
Market
In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States.
Journal of Economic Perspectives
December 1, 2015

Research

The Just Price of Cancer Drugs and the Growing Cost of Cancer Care: Oncologists Need to Be Part of the Solution

Chemotherapies
Costs of Care
Drug Prices
Dr. David Pfister of Memorial Sloan Kettering Cancer Center summarizes the work that Dr. Bach and colleagues regarding the high cost of cancer treatments and alternative pricing methods.
The Journal of Clinical Oncology
September 3, 2013

Research

Cost Consequences of the 340B Drug Discount Program

340B
Chemotherapies
Costs of Care
Drs. Rena Conti and Peter Bach report on the unintended consequences of the 340B drug discount program.
The Journal of the American Medical Association
May 15, 2013

Research

Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists

Chemotherapies
Providers
In this study, Dr. Bach and coauthors find that patent-protected chemotherapies are used approximately 30% of the time for for off-label indications.
Journal of Clinical Oncology
March 20, 2013

Research

In Cancer Care, Cost Matters

Chemotherapies
Drug Prices
Payment
MSK physicians, including Dr. Bach, announce their refusal to offer a cancer drug to patients because of its "phenomenally expensive" cost.
The New York Times
October 14, 2012

No Results Found

©Memorial Sloan Kettering Cancer Center, 2019
  • Terms & Conditions
  • Contact
  • MSKCC